Express News | Dian Diagnostics Group: is currently collaborating with partners to explore the medical diagnostic applications of the HW cloud and the Pangu model.
Dian Diagnostics Group (300244.SZ): The size of accounts receivable matches the characteristics of the business model and the growth of revenue, mainly from medical institutions and government.
On June 12, Gelonhui reported that dian diagnostics group (300244.SZ) stated on an investor platform that the company puts a great deal of emphasis on the efficiency of accounts receivable collection. Not only are accounts receivable collection tied to employee performance and bonuses, but also a department specifically focused on accounts receivable management has been established, from the group to the subsidiaries to the business personnel, layer by layer decomposition, establishing a dynamic evaluation and monitoring system. At present, the company's accounts receivable scale matches the characteristics of the business model and revenue growth, mainly from medical institutions and governments.
Dian Diagnostics Group (300244.SZ) plans to distribute 0.6 yuan per 10 shares, with the ex-rights and ex-dividends date on June 13th.
Dian Diagnostics Group (300244.SZ) announced that it plans to distribute annual equity dividends to all shareholders in 2023: 0.6 yuan (including tax) cash dividend per 10 shares. The ex-dividend and ex-right date is June 13, 2024.
Dian Diagnosis (300244.SZ): We are working with partners to discuss the implementation of medical diagnostic applications in the field of HW Cloud and the Pangu Large Model
On May 24, Ge Longhui | Dian Diagnosis (300244.SZ) said on the investor interactive platform that the company is working with partners to discuss the implementation of medical diagnosis applications in the field of HW Cloud and the Pangu Big Model.
Express News | Dean's diagnosis: The company currently has no low-altitude economic layout
Dian Diagnosis (300244.SZ): Currently, the first overseas medical testing laboratory opened in Vietnam on April 19, 2024
On May 16, Ge Longhui | Dian Diagnosis (300244.SZ) said at the performance briefing that the company's first overseas medical testing laboratory has now opened in Vietnam on April 19, 2024. You can follow the company's regular reports on overseas business revenue.
Dean Diagnosis (300244) Review Report: Good receivables trend, ICL grew steadily in the first quarter
Incident: Recently, the company released its 2023 annual report: annual revenue of 13.408 billion yuan, a year-on-year decrease of 33.89%, mainly due to a decrease in testing demand related to public health events and a sharp decline in the company's diagnostic service revenue
Dean Diagnosis (300244): Short-term performance is under pressure, ICL growth is steady
Key points: Revenue fell 33.89% year on year, net profit after deducting non-return to mother fell 81.90% year on year incident: Recently, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 134.
Dian Diagnosis (300244.SZ) has repurchased a total of 5,529,500 shares at a cost of 100 million yuan
Zhitong Finance App News, Dean Diagnosis (300244.SZ) announced that as of April 30, 2024, the company had repurchased 5,529,500 shares of the company's shares through a dedicated securities account, accounting for 0.88% of the company's current total share capital. The highest transaction price was 18.91 yuan/share, the minimum transaction price was 15.01 yuan/share, and the total transaction amount was RMB 100 million (excluding transaction fees).
Dean Diagnosis (300244): Impairment calculation affects apparent performance First quarter results are lower than expected
Event: The company released its report for the first quarter of 2024. In the first quarter of 2024, it achieved operating income of 2,973 billion yuan (-8.01%), net profit to mother of 0.23 million yuan (-85.54%), deducting non-net profit
Huaan Securities released a research report on April 28 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) short-term performance is under pressure, and the scale effect remains the same; 2) regu
Huaan Securities released a research report on April 28 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) short-term performance is under pressure, and the scale effect remains the same; 2) regular business continues to grow, and the growth rate of special inspection business is stable. (Mainichi Keizai Shimbun)
Dean Diagnosis (300244.SZ): Net profit of 23.1705 million yuan in the first quarter decreased by 85.54% year on year
On April 26, Ge Longhui (300244.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 2,973 billion yuan, down 8.01% year on year; net profit attributable to shareholders of listed companies was 23.1705 million yuan, down 85.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.363 million yuan, down 83.01% year on year; basic earnings per share were 0.0371 yuan.
Dean Diagnosis (300244): Annual apparent performance is under pressure, regular business operations are steady
Incident: The company released its 2023 annual report. The company achieved operating income of 13.408 billion yuan (-33.89%) and net profit to mother of 307 million yuan (-78.56%) in 2023, after deducting non-net
Dean Diagnosis (300244): Regular diagnostic services have grown steadily and operating cash flow has improved significantly
The impact of COVID-19 is expected to clear up, and the company is expected to enter a continuous growth channel. In 2023, the company achieved operating income of 13.408 billion yuan, a year-on-year decrease of 33.89%; realized net profit to mother of 307 million yuan, a year-on-year decrease of 78.56 million yuan
Zhongtai Securities released a research report on April 23 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) 81.90% decrease compared to the ratio; 2) fixed cost amortization, accounts receivabl
Zhongtai Securities released a research report on April 23 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) 81.90% decrease compared to the ratio; 2) fixed cost amortization, accounts receivable impairment, etc. affect short-term profitability; 3) smooth COVID-19 payables and continued healthy operating cash flow; 4) routine ICL recovery is good, and high-quality development strategies for diagnostic services continue to be deepened; 5) disease solution upgrades and iterations, precision centers, cooperation and co-construction have borne fruit; 6) new technologies and platforms have accelerated transformation, and AD and other features are gradually being implemented. (Mainichi Keizai Shimbun)
Earnings Miss: Dian Diagnostics Group Co.,Ltd. Missed EPS By 53% And Analysts Are Revising Their Forecasts
As you might know, Dian Diagnostics Group Co.,Ltd. (SZSE:300244) last week released its latest annual, and things did not turn out so great for shareholders. It wasn't a great result overall - wh
Express News | Dian Diagnostics Vietnam subsidiary opens international business and enters a new stage of “service+product”
Dian Diagnosis (300244.SZ) announced its 2023 annual results, with net profit of 307 million yuan, a decrease of 78.56%
Zhitong Finance App News, Dean Diagnosis (300244.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 13.408 billion yuan, a year-on-year decrease of 33.89%. Achieved net profit of 307 million yuan attributable to shareholders of listed companies, a year-on-year decrease of 78.56%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 295 million yuan, a year-on-year decrease of 81.90%. Basic earnings per share were $0.4918. It is proposed to distribute a cash dividend of 0.60 yuan (tax included) for every 10 shares to all shareholders. During the reporting period, the diagnostic service business was put into operation
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
Dean Diagnosis (300244.SZ): 0.80% of shares have been repurchased cumulatively
Gelonghui, April 2, 丨 Dean Diagnosis (300244.SZ) announced that as of March 29, 2024, the company had repurchased 5,032,500 shares of the company's shares through centralized bidding transactions through special securities accounts, accounting for 0.80% of the company's current total share capital. The highest transaction price was RMB 18.91 per share, the minimum transaction price was RMB 17.35 per share, and the total transaction amount was RMB 91,320,939 (excluding transaction fees).
No Data